Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Recruiting

Phase 2

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Sponsor:

Chronic Lymphocytic Leukemia Research Consortium

Code:

NCT00628238

Conditions

Chronic Lymphocytic Leukemia

CLL

Untreated

Front-line

First-Line

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide and Rituximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-05. This information was provided to ClinicalTrials.gov by Chronic Lymphocytic Leukemia Research Consortium on 2010-09-10.